MCID: INS002
MIFTS: 52

in Situ Carcinoma

Categories: Cancer diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for in Situ Carcinoma

MalaCards integrated aliases for in Situ Carcinoma:

Name: in Situ Carcinoma 12 15
Carcinoma in Situ 44 70

Classifications:



External Ids:

Disease Ontology 12 DOID:8719
ICD9CM 34 230-234.99
MeSH 44 D002278
NCIt 50 C2917
SNOMED-CT 67 109355002
ICD10 32 D09.9
UMLS 70 C0007099

Summaries for in Situ Carcinoma

Disease Ontology : 12 A carcinoma that is an early development defined by the absence of invasion of surrounding tissues.

MalaCards based summary : in Situ Carcinoma, also known as carcinoma in situ, is related to comedo carcinoma and bladder cancer. An important gene associated with in Situ Carcinoma is PGR (Progesterone Receptor), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Ondansetron and Ropivacaine have been mentioned in the context of this disorder. Affiliated tissues include breast, cervix and lymph node, and related phenotypes are cellular and cardiovascular system

Wikipedia : 73 Carcinoma in situ (CIS) is a group of abnormal cells. While they are a form of neoplasm, there is... more...

Related Diseases for in Situ Carcinoma

Diseases in the in Situ Carcinoma family:

Pre-Malignant Neoplasm Eye Carcinoma in Situ

Diseases related to in Situ Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 722)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 33.1 TP53 PGR ESR1 ERBB2
2 bladder cancer 32.0 TP53 MIR143 MIR139 MIR126 ERBB2 EGFR
3 vulvar intraepithelial neoplasia 31.6 TP53 CDH1
4 breast carcinoma in situ 31.5 TP53 PGR MIR342 MIR181A1 MIR143 KRT5
5 vulva cancer 31.4 TP53 ERBB2 EGFR
6 gynecomastia 31.3 PGR ESR1 ERBB2
7 intraductal papilloma 31.3 PGR KRT5 ESR1 ERBB2
8 cervix carcinoma 31.2 TP53 PGR ESR1 ERBB2 EGFR CDH1
9 tubular adenocarcinoma 31.2 PGR ESR1 ERBB2 EGFR CDH1
10 sebaceous adenocarcinoma 31.1 TP53 KRT5 ERBB2
11 cervical squamous cell carcinoma 31.1 TP53 MIR143 EGFR CDH1
12 small cell carcinoma 31.1 TP53 ERBB2 EGFR BRCA2
13 basal cell carcinoma 31.1 TP53 MIR143 KRT5 EGFR CDH1
14 intrahepatic cholangiocarcinoma 31.1 TP53 ERBB2 EGFR CDH1
15 cholangiocarcinoma 31.1 TP53 ERBB2 EGFR CDH1
16 adenosquamous carcinoma 31.0 TP53 KRT5 EGFR
17 larynx cancer 30.9 TP53 MIR143 MIR139 EGFR
18 breast cancer 30.8 TP53 PGR NR3C1 MIR181A1 MIR143 MIR126
19 female breast cancer 30.8 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
20 apocrine adenocarcinoma 30.7 PGR KRT5 ESR1 ERBB2 EGFR
21 inverted papilloma 30.7 TP53 KRT5 EGFR
22 ductal carcinoma in situ 30.7 TP53 PGR KRT5 ESR1 ERBB2 EGFR
23 mammary paget's disease 30.7 PGR ESR1 ERBB2 EGFR
24 papilloma 30.7 TP53 KRT5 ERBB2 EGFR
25 cholecystitis 30.7 TP53 EGFR CDH1
26 endometrial hyperplasia 30.7 TP53 PGR ESR1
27 tetraploidy 30.6 BRCA2 BRCA1
28 cystadenocarcinoma 30.6 TP53 PGR ERBB2 BRCA1
29 hypertrophy of breast 30.6 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
30 hereditary breast ovarian cancer syndrome 30.6 TP53 ERBB2 BRCA2 BRCA1
31 bronchiolo-alveolar adenocarcinoma 30.6 MIR126 EGFR CDH1
32 bladder disease 30.5 MIR181A1 MIR143 MIR139 MIR126
33 gastric cancer, hereditary diffuse 30.5 TP53 CDH1 BRCA2 BRCA1
34 mucinous adenocarcinoma 30.5 TP53 PGR ESR1 ERBB2 EGFR
35 lobular neoplasia 30.5 TP53 PGR KRT5 ESR1 ERBB2 CT45A10
36 adenocarcinoma 30.5 TP53 ERBB2 EGFR CDH1 BRCA2 BRCA1
37 carcinosarcoma 30.5 TP53 PGR ERBB2 EGFR CDH1
38 bilateral breast cancer 30.5 TP53 PGR ESR1 ERBB2 CDH1 BRCA2
39 peutz-jeghers syndrome 30.5 TP53 EGFR BRCA2
40 breast fibroadenoma 30.5 TP53 PGR ESR1 ERBB2 CT45A10 BRCA1
41 breast adenoid cystic carcinoma 30.5 PGR ESR1 ERBB2
42 breast squamous cell carcinoma 30.5 TP53 KRT5 ERBB2
43 lung squamous cell carcinoma 30.4 TP53 EGFR CDH1 BRCA1
44 colon adenocarcinoma 30.4 TP53 ESR1 ERBB2 EGFR CDH1
45 microglandular adenosis 30.4 TP53 PGR ESR1 ERBB2 EGFR CDH1
46 breast-ovarian cancer, familial 2 30.4 BRCA2 BRCA1
47 diffuse large b-cell lymphoma 30.4 TP53 MIR181A1 MIR143 MIR139 MIR126
48 vaginal cancer 30.4 TP53 PRDX2 PGR ESR1
49 skin melanoma 30.4 TP53 ERBB2 EGFR CDH1 BRCA1
50 verrucous carcinoma 30.4 TP53 KRT5 EGFR

Graphical network of the top 20 diseases related to in Situ Carcinoma:



Diseases related to in Situ Carcinoma

Symptoms & Phenotypes for in Situ Carcinoma

MGI Mouse Phenotypes related to in Situ Carcinoma:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
2 cardiovascular system MP:0005385 10.25 AGTR1 BRCA1 CDH1 EGFR ERBB2 ESR1
3 digestive/alimentary MP:0005381 10.22 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
4 immune system MP:0005387 10.18 AGTR1 BRCA1 BRCA2 CDH1 EGFR ESR1
5 integument MP:0010771 10.15 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
6 endocrine/exocrine gland MP:0005379 10.13 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
7 embryo MP:0005380 10.11 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
8 limbs/digits/tail MP:0005371 9.92 BRCA1 BRCA2 EGFR ERBB2 ESR1 KRT5
9 neoplasm MP:0002006 9.86 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
10 normal MP:0002873 9.81 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
11 renal/urinary system MP:0005367 9.56 AGTR1 BRCA1 EGFR ESR1 FKBP4 ITGB4
12 reproductive system MP:0005389 9.32 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1

Drugs & Therapeutics for in Situ Carcinoma

Drugs for in Situ Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ondansetron Approved Phase 4 99614-02-5 4595
2
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
3
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
4 Mitomycins Phase 4
5 Narcotics Phase 4
6 Analgesics Phase 4
7 Anesthetics, General Phase 4
8 Anesthetics, Intravenous Phase 4
9 Anesthetics, Local Phase 4
10 Analgesics, Opioid Phase 4
11
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
12
Aminolevulinic acid Approved Phase 3 106-60-5 137
13
Aluminum sulfate Approved Phase 3 10043-01-3
14
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
15
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
16
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
17
Iron Approved Phase 3 7439-89-6 23925 29936
18
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
19
Cidofovir Approved Phase 3 113852-37-2 60613
20
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
21
BCG vaccine Approved, Investigational Phase 2, Phase 3
22
Valrubicin Approved Phase 2, Phase 3 56124-62-0 41744
23
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
24
Afimoxifene Investigational Phase 2, Phase 3 68392-35-8
25 Immunologic Factors Phase 3
26 Antibiotics, Antitubercular Phase 3
27 Anti-Bacterial Agents Phase 3
28 Estrogens, Conjugated (USP) Phase 3
29 Mandelic Acids Phase 3
30 Parasympatholytics Phase 3
31 Cholinergic Antagonists Phase 3
32 Muscarinic Antagonists Phase 3
33 Contraceptives, Oral Phase 3
34 Contraceptive Agents Phase 3
35
Liposomal doxorubicin Phase 3 31703
36 Anti-Allergic Agents Phase 3
37 Keyhole-limpet hemocyanin Phase 3
38 Contraceptive Agents, Male Phase 3
39
Medroxyprogesterone Phase 3 520-85-4 10631
40 Immunoglobulins Phase 3
41 Antibodies Phase 3
42 Antibodies, Monoclonal Phase 3
43 Immunoglobulins, Intravenous Phase 3
44 Hydroxytamoxifen Phase 2, Phase 3
45 Vaccines Phase 3
46 Adjuvants, Immunologic Phase 3
47 Immunosuppressive Agents Phase 2, Phase 3
48 Antimetabolites Phase 2, Phase 3
49
Epirubicin Approved Phase 2 56420-45-2 41867
50
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639

Interventional clinical trials:

(show top 50) (show all 380)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
2 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
3 Electronic Xoft Intersociety Brachytherapy Trial Completed NCT00742222 Phase 4
4 A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip. Completed NCT00868088 Phase 4
5 Clinical Trial to Compare Topical Interferon Alfa 2b And Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia Completed NCT02199327 Phase 4 Mitomycin C;Interferon Alfa-2b
6 The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. A Double Blind, Randomised, Placebo Controlled Trial. Recruiting NCT04248179 Phase 4 Ropivacaine injection;Saline 0.9%;Sufentanil and PONV prophylaxis
7 An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR) Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
8 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Unknown status NCT02669459 Phase 3 Imiquimod
9 Optimal Wound Care After Simplex or Modified Radical Mastectomy With or Without Axillary Lymphadenectomy Placement of a Drain Versus the Use of Adaptive Skin Sutures; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
10 Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast Unknown status NCT00402519 Phase 3
11 A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes Completed NCT02961790 Phase 3 Oxybutynin Chloride
12 Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG) Completed NCT01316874 Phase 2, Phase 3 Valrubicin, 800 mg
13 Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer Completed NCT00757302 Phase 3
14 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Completed NCT01735006 Phase 3
15 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
16 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
17 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
18 Phase III Randomized Double-Blind Study of Mometasone Furoate Versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy Completed NCT00438659 Phase 3 mometasone furoate
19 A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
20 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
21 Genetic Counseling for Newly Diagnosed Breast Cancer Patients Completed NCT00262899 Phase 3
22 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN) Completed NCT00106691 Phase 3 Toremifene 20 mg;Placebo
23 Diagnosis of Intraepithelial Neoplasia in Patients With Long Standing Ulcerative Colitis With Chromoscopic Guided Endomicroscopy Completed NCT00352404 Phase 3
24 An Open, Comparative, Within Patient, Controlled Phase III, Multicenter Study Of HEXVIX Fluorescence Cystoscopy And White Light Cystoscopy In the Detection Of Carcinoma In Situ In Patients With Bladder Cancer Completed NCT00052637 Phase 3 hexaminolevulinate
25 A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer Completed NCT00006034 Phase 3 doxorubicin hydrochloride
26 A Prospective Randomized Trial for the Comparison of Two BCG Strains (Bacille Calmette-Guerin) in the Prophylaxis of Papollary Bladder Tumors Stage Ta and T1 and Treatment of Carcinoma in Situ Completed NCT00003779 Phase 3
27 A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
28 A Phase 3 Study of CG0070 in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG) Recruiting NCT04452591 Phase 3
29 Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women Recruiting NCT01905046 Phase 3 metformin hydrochloride
30 Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer Recruiting NCT03077841 Phase 2, Phase 3
31 Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk and Estrogen Receptor-Positive Ductal Carcinoma in Situ of Breast: an International Open-label Randomized Non-inferiority Trial Recruiting NCT04046159 Phase 3 Low-dose tamoxifen
32 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy Recruiting NCT02954874 Phase 3
33 Sentinel Lymph Node Biopsy in Ductal Cancer in Situ or Unclear Lesions of the Breast and How to Not do it. An Open-label, Phase 3, Randomised Controlled Trial. (SentiNot 2.0). Recruiting NCT04722692 Phase 3
34 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy Active, not recruiting NCT00769379 Phase 3
35 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
36 A Randomized Web-Based Physical Activity Intervention Among Children and Adolescents With Cancer Active, not recruiting NCT03223753 Phase 3
37 A Multicentric Phase III Trial Evaluating the Impact of a Radiation Boost (16Gy) After Breast Conserving Surgery and a Whole Breast Irradiation (50Gy) for DCIS Active, not recruiting NCT00907868 Phase 3
38 Randomized Placebo-controlled Phase III Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3 Tamoxifen;placebo
39 Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
40 A Randomised Phase III Study of Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
41 International Breast Cancer Intervention Study II (IBIS-II) (DCIS) Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
42 Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia Active, not recruiting NCT01861535 Phase 3 Imiquimod
43 Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG Active, not recruiting NCT02449239 Phase 3
44 A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ Not yet recruiting NCT04570956 Phase 2, Phase 3 Tamoxifen;Topical 4-OHT( 4-hydroxytamoxifen)gel 2 mg/each breast/day;Placebo
45 A Randomised, Double-Blind, Placebo-Controlled, Phase III Study to Investigate the Efficacy of Presurgical 9-valent HPV Vaccination in Women Treated With LEEP for CIN 2+ and Initially Invasive Cervical Cancer. Not yet recruiting NCT03848039 Phase 3 Placebo
46 A Phase III, Randomized, One-site, Pilot, Open-label, Parallel Groups Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males Not yet recruiting NCT04055142 Phase 3 cidofovir 1% topical ointment;sinecatechins 10% topical ointment
47 An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG Terminated NCT01438112 Phase 2, Phase 3
48 A PHASE 3B, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH VALRUBICIN VERSUS NO MAINTENANCE, IN SUBJECTS TREATED WITH VALRUBICIN INDUCTION FOR CARCINOMA IN SITU (CIS) OF THE BLADDER Terminated NCT01310803 Phase 3 VALSTAR - Maintenance Therapy
49 ITIC2 Trial - Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial Terminated NCT01283763 Phase 3 Topical Imiquimod
50 A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer Terminated NCT01200992 Phase 3

Search NIH Clinical Center for in Situ Carcinoma

Cochrane evidence based reviews: carcinoma in situ

Genetic Tests for in Situ Carcinoma

Anatomical Context for in Situ Carcinoma

MalaCards organs/tissues related to in Situ Carcinoma:

40
Breast, Cervix, Lymph Node, Testis, Pancreas, Prostate, Colon

Publications for in Situ Carcinoma

Articles related to in Situ Carcinoma:

(show top 50) (show all 17875)
# Title Authors PMID Year
1
Adolescent use of hair dyes, straighteners and perms in relation to breast cancer risk. 61
33252833 2021
2
Symptomatic ductal carcinoma in situ (DCIS): Upstaging risk and predictors. 61
33360004 2021
3
Papillomas and probable in situ carcinoma in association with a novel papillomavirus in a red-billed gull (Chroicocephalus novaehollandiae scopulinus). 61
33550506 2021
4
Postneoadjuvant Pure and Predominantly Pure Intralymphatic Breast Carcinoma: Case Series and Literature Review. 61
33105157 2021
5
Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. 61
33113154 2021
6
Upgrade rate of intraductal papilloma diagnosed on core needle biopsy in a single institution. 61
33159966 2021
7
The Role of Imaging in Health Screening: Overview, Rationale of Screening, and Screening Economics. 61
32409140 2021
8
Mohs micrographic surgery for male genital tumors: Local recurrence rates and patient-reported outcomes. 61
33279645 2021
9
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. 61
33419683 2021
10
Digital Mammography Has Persistently Increased High-Grade and Overall DCIS Detection Without Altering Upgrade Rate. 61
33594910 2021
11
Once Daily Versus Twice Daily External Beam Accelerated Partial Breast Irradiation: A Randomized Prospective Study. 61
33714527 2021
12
Mixed-Methods Study to Predict Upstaging of DCIS to Invasive Disease on Mammography. 61
32783550 2021
13
The Myoepithelial Cells of Salivary Intercalated Duct-type Intraductal Carcinoma Are Neoplastic: A Study Using Combined Whole-slide Imaging, Immunofluorescence, and RET Fluorescence In Situ Hybridization. 61
33086236 2021
14
The utility of intraoperative retroareolar margin frozen section assessment and the management of atypical epithelial proliferative lesions at the retroareolar margin in nipple-sparing mastectomies. 61
33444902 2021
15
Intraoral Ultrasonographic Features of Tongue Cancer and the Incidence of Cervical Lymph Node Metastasis. 61
33031775 2021
16
Male Breast Cancer in Australia. 61
31957255 2021
17
Deep learning-based grading of ductal carcinoma in situ in breast histopathology images. 61
33608619 2021
18
Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes. 61
33180236 2021
19
Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy. 61
33675490 2021
20
Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence. 61
33140128 2021
21
Impact of Cavity Shave Margins on Margin Status in Patients with Pure Ductal Carcinoma In Situ. 61
33346081 2021
22
Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast. 61
33795819 2021
23
Novel treatment of upper tract urothelial carcinoma in situ with docetaxel in BCG refractory patients. 61
32958446 2021
24
TERT promoter mutations in penile squamous cell carcinoma: high frequency in non-HPV-related type and association with favorable clinicopathologic features. 61
33635430 2021
25
Expression profiles of metallothionein-I/II and megalin/LRP-2 in uterine cervical squamous lesions. 61
33084977 2021
26
Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation. 61
33654083 2021
27
Routine panendoscopy in oral squamous cell cancer patients: mandatory or facultative? 61
32607829 2021
28
Cervical cancer incidence by ethnic group in Scotland from 2008 to 2017: A population-based study. 61
33715256 2021
29
Upgrade rates and outcomes of screen-detected atypical intraductal epithelial proliferation (AIDEP) diagnosed on core needle biopsy. 61
33749633 2021
30
Not All Cases of Mammary Paget's Disease are Cytokeratin-7 Positive: A Challenging Diagnosis! 61
33750236 2021
31
Could Extension Into the Lacrimal Gland and Sac Thwart Topical Chemotherapy for Intraepithelial Sebaceous Carcinoma? 61
33782326 2021
32
Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. 61
33263939 2021
33
Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component. 61
33335279 2021
34
Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors. 61
33685728 2021
35
Visualization of lymphatic vascular invasion in breast cancer by multiphoton microscopy. 61
32681221 2021
36
Time from breast cancer diagnosis to treatment among Idaho's National Breast and Cervical Cancer Early Detection Program population, 2011-2017. 61
33665701 2021
37
Cribriform colon cancer: a morphological growth pattern associated with extramural venous invasion, nodal metastases and microsatellite stability. 61
33782192 2021
38
Conjunctival Carcinomas Arising in the Anophthalmic Socket. 61
33705043 2021
39
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer. 61
33650041 2021
40
Effects of fluorescent light cystoscopy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. 61
33711534 2021
41
Imaging of Bladder Cancer: Standard Applications and Future Trends. 61
33804350 2021
42
Genetic variability in 13q33 and 9q34 is linked to aggressiveness patterns and a higher risk of progression of non-muscle-invasive bladder cancer at the time of diagnosis. 61
32975901 2021
43
Clinical outcomes after intravesical bacillus Calmette-Guérin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019. 61
33734503 2021
44
Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System. 61
33787908 2021
45
Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC). 61
33012593 2021
46
Breast MRI: False-Negative Results and Missed Opportunities. 61
33739893 2021
47
Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. 61
33710917 2021
48
High-Risk Lesions Detected by MRI-Guided Core Biopsy: Upgrade Rates at Surgical Excision and Implications for Management. 61
33439046 2021
49
Development of a digital breast phantom for photoacoustic computed tomography. 61
33796361 2021
50
A case of endocrine mucin-producing sweat gland carcinoma with distant metastasis. 61
33660318 2021

Variations for in Situ Carcinoma

Expression for in Situ Carcinoma

Search GEO for disease gene expression data for in Situ Carcinoma.

Pathways for in Situ Carcinoma

Pathways related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 TP53 ERBB2 EGFR CDH1 BRCA2
2 12.64 TP53 ESR1 ERBB2 EGFR CDH1 BRCA2
3
Show member pathways
12.47 TP53 ESR1 ERBB2 EGFR CDH1 BRCA2
4
Show member pathways
12.22 TP53 PGR ESR1 ERBB2 EGFR CDH1
5 12.12 TP53 ESR1 ERBB2 EGFR
6 11.92 PGR FKBP4 ESR1 EGFR
7 11.82 TP53 ESR1 EGFR CDH1 BRCA2 BRCA1
8
Show member pathways
11.79 PGR ESR1 ERBB2 EGFR
9
Show member pathways
11.76 ESR1 ERBB2 EGFR
10 11.74 FKBP4 EGFR BRCA1
11
Show member pathways
11.73 PGR NR3C1 ESR1
12 11.72 TP53 MIR342 MIR181A1 MIR143 MIR126 ERBB2
13
Show member pathways
11.69 TP53 BRCA2 BRCA1
14 11.65 TP53 NR3C1 KRT5 FKBP4
15 11.62 TP53 ERBB2 BRCA1
16 11.59 ERBB2 EGFR CDH1
17 11.57 TP53 ERBB2 EGFR
18 11.57 TP53 ERBB2 EGFR CDH1
19
Show member pathways
11.54 PGR NR3C1 ESR1
20 11.52 TP53 ERBB2 BRCA1
21 11.46 ITGB4 ERBB2 BRCA1
22 11.05 ITGB4 ERBB2 EGFR CDH1
23 10.57 NR3C1 FKBP4

GO Terms for in Situ Carcinoma

Cellular components related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.17 TP53 NR3C1 FKBP4 ESR1 EGFR BRCA2
2 basal plasma membrane GO:0009925 9.13 ITGB4 ERBB2 EGFR

Biological processes related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.91 TP53 ESR1 EGFR CDH1 BRCA2 BRCA1
2 regulation of apoptotic process GO:0042981 9.86 TP53 PRDX2 ESR1 BRCA1
3 double-strand break repair GO:0006302 9.65 TP53 BRCA2 BRCA1
4 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.55 TP53 EGFR
5 positive regulation of protein kinase B signaling GO:0051897 9.55 MIR143 MIR126 ESR1 ERBB2 EGFR
6 hemidesmosome assembly GO:0031581 9.54 KRT5 ITGB4
7 positive regulation of blood vessel endothelial cell migration GO:0043536 9.54 MIR342 MIR143 MIR126
8 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.52 TP53 ESR1
9 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.51 TP53 ESR1
10 angiotensin-activated signaling pathway GO:0038166 9.49 MIR143 AGTR1
11 hydrogen peroxide metabolic process GO:0042743 9.46 PRDX2 EGFR
12 negative regulation of ERBB signaling pathway GO:1901185 9.4 ERBB2 EGFR
13 cellular response to indole-3-methanol GO:0071681 9.32 CDH1 BRCA1
14 chordate embryonic development GO:0043009 9.26 BRCA2 BRCA1
15 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.13 TP53 BRCA2 BRCA1
16 intracellular steroid hormone receptor signaling pathway GO:0030518 8.8 PGR NR3C1 ESR1

Molecular functions related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.77 TP53 PGR ESR1 EGFR BRCA1
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.65 MIR342 MIR181A1 MIR143 MIR139 MIR126
3 protein phosphatase binding GO:0019903 9.63 TP53 ERBB2 EGFR
4 ATPase binding GO:0051117 9.61 PGR ESR1 EGFR
5 identical protein binding GO:0042802 9.61 TP53 PGR ESR1 ERBB2 EGFR CT45A10
6 nuclear receptor activity GO:0004879 9.5 PGR NR3C1 ESR1
7 nitric-oxide synthase regulator activity GO:0030235 9.4 ESR1 EGFR
8 steroid binding GO:0005496 9.33 PGR NR3C1 ESR1
9 mRNA 3'-UTR binding GO:0003730 9.02 TP53 MIR181A1 MIR143 MIR139 MIR126

Sources for in Situ Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....